Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.57 and traded as high as $0.63. Xtant Medical shares last traded at $0.61, with a volume of 31,995 shares traded.
Xtant Medical Price Performance
The company has a quick ratio of 1.16, a current ratio of 2.47 and a debt-to-equity ratio of 0.46. The stock has a market cap of $81.32 million, a P/E ratio of -15.60 and a beta of -0.21. The business's 50-day simple moving average is $0.63 and its two-hundred day simple moving average is $0.57.
Hedge Funds Weigh In On Xtant Medical
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC boosted its position in Xtant Medical by 500.3% during the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company's stock worth $50,543,000 after purchasing an additional 57,000,000 shares during the period. AWM Investment Company Inc. bought a new position in shares of Xtant Medical in the second quarter valued at approximately $4,875,000. Renaissance Technologies LLC boosted its position in shares of Xtant Medical by 15.0% in the fourth quarter. Renaissance Technologies LLC now owns 798,033 shares of the medical device company's stock valued at $354,000 after acquiring an additional 103,825 shares during the period. Crescent Grove Advisors LLC boosted its position in shares of Xtant Medical by 94.3% in the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company's stock valued at $304,000 after acquiring an additional 200,000 shares during the period. Finally, Mink Brook Asset Management LLC boosted its position in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock valued at $81,000 after acquiring an additional 60,997 shares during the period. Institutional investors own 69.33% of the company's stock.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Further Reading
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
